Biotech · Private company
Rhizen Pharmaceuticals SA
Track this companyFree. Adds Rhizen Pharmaceuticals SA to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- RomidepsinPhase 2 · T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TenalisibPhase 2 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TenalisibPhase 2 · T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TenalisibPhase 2 · Peripheral T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Tenalisib,Phase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Classical Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RP4010Phase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RP6530Phase 1 · Lymphoma, T-Cell, PeripheralClinicalTrials.gov · fetched Nov 12, 2026
- RP7214Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- TenalisibPhase 1 · Classical Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLPHASE2 · WITHDRAWN · started Jan 1, 2023ClinicalTrials.gov NCT05239910 · fetched Nov 12, 2026
- A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult SubjectsPHASE1 · COMPLETED · started Dec 29, 2020ClinicalTrials.gov NCT04680429 · fetched Nov 12, 2026
- Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaPHASE1_PHASE2 · COMPLETED · started Mar 12, 2019ClinicalTrials.gov NCT03770000 · fetched Nov 12, 2026
- Compassionate Use Study of Tenalisib (RP6530)PHASE1_PHASE2 · COMPLETED · started Nov 28, 2018ClinicalTrials.gov NCT03711604 · fetched Nov 12, 2026
- Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)PHASE2 · COMPLETED · started Nov 25, 2018ClinicalTrials.gov NCT03711578 · fetched Nov 12, 2026
- Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLPHASE1 · TERMINATED · started Jul 18, 2018ClinicalTrials.gov NCT03471351 · fetched Nov 12, 2026
- Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory LymphomasPHASE1 · TERMINATED · started May 11, 2017ClinicalTrials.gov NCT03119467 · fetched Nov 12, 2026
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaPHASE1 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02567656 · fetched Nov 12, 2026